Works matching IS 11732563 AND DT 2023 AND VI 43 AND IP 8
Results: 8
Tislelizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy as First-Line Treatment for Chinese Patients with Advanced Esophageal Squamous Cell Carcinoma: A Cost-Effectiveness Analysis.
- Published in:
- Clinical Drug Investigation, 2023, v. 43, n. 8, p. 643, doi. 10.1007/s40261-023-01295-2
- By:
- Publication type:
- Article
Avacopan, a Novel Competitive C5a Receptor Antagonist, for Severe Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis.
- Published in:
- Clinical Drug Investigation, 2023, v. 43, n. 8, p. 595, doi. 10.1007/s40261-023-01298-z
- By:
- Publication type:
- Article
Does Opioid Use Disorder Matter for Health Care Utilization Among Lung Cancer Patients? Evidence from U.S. Hospitals During 2016–2020.
- Published in:
- Clinical Drug Investigation, 2023, v. 43, n. 8, p. 635, doi. 10.1007/s40261-023-01297-0
- By:
- Publication type:
- Article
Absorption, Metabolism, and Excretion of [<sup>14</sup>C]-Tolebrutinib After Oral Administration in Humans, Contribution of the Metabolites to Pharmacological Activity.
- Published in:
- Clinical Drug Investigation, 2023, v. 43, n. 8, p. 653, doi. 10.1007/s40261-023-01296-1
- By:
- Publication type:
- Article
Correction to: Olipudase Alfa in Non-CNS Manifestations of Acid Sphingomyelinase Deficiency: A Profile of Its Use.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Evaluating the Association of Montelukast Use on Neuropsychiatry-Related Healthcare Utilization and Depression in COVID-19-Hospitalized Veterans: A Nationwide VA Observational Cohort Study.
- Published in:
- Clinical Drug Investigation, 2023, v. 43, n. 8, p. 605, doi. 10.1007/s40261-023-01292-5
- By:
- Publication type:
- Article
Healthcare Professional (HCP) and Patient Usability Evaluation and Preferences of Two Auto-injector Devices for Self-Injection of Biosimilars, SB4 and SB5: A Literature Review.
- Published in:
- Clinical Drug Investigation, 2023, v. 43, n. 8, p. 579, doi. 10.1007/s40261-023-01284-5
- By:
- Publication type:
- Article
Cancer Drugs Reimbursed with Limited Evidence on Overall Survival and Quality of Life: Do Follow-Up Studies Confirm Patient Benefits?
- Published in:
- Clinical Drug Investigation, 2023, v. 43, n. 8, p. 621, doi. 10.1007/s40261-023-01285-4
- By:
- Publication type:
- Article